Printer Friendly

GenSci Expects Topical Molgramostim Gel Approval in 2007.

SHANGHAI, China -- GeneScience Pharmaceuticals Co., Ltd. (GenSci) announced today that the company's new drug, Genfulin[TM], a topical gel indicated for the treatment of wound healing, is expected to get approval by China's SFDA in early 2007.

The active ingredient in Genfulin[TM] is molgramostim (human granulocyte-macrophage colony stimulating factor, hGM-CSF (rDNA origin). GenSci has been the top biopharmaceutical manufacturer for Jintropin(TM) somatropin (human growth hormone, hGH), Scimax(TM) filgrastim (human granulocyte colony stimulating factor, G-CSF) and molgramostim in China.

"With the unique innovative formulation, Genfulin[TM] marks the major step in GenSci's transition to manufacturing biological supergenerics," according to Dr. Lei Jin, CEO of GenSci.

Based on the current indications of molgramostim, Genfulin[TM] gel was designed for new indications in wound healing with its novel and unique formulation. Most importantly, clinical trials of Genfulin[TM] have confirmed its efficacy in actively accelerating wound healing, increasing wound tearing-resistance, and reducing, even avoiding, scar proliferation in burn patients. Similar effects have also been observed in chronic ulcer patients, including those with diabetic foot ulcer. Overall, Genfulin[TM] gel has been shown to improve the quality of wound healing significantly with a good safety profile, according to results obtained from clinical trials.

Genfulin[TM] gel is applied to wound areas directly in patients with burn, scald or ulcer to speed up the healing. GenSci holds a patent for Genfulin[TM], which was developed with GenSci's proprietary technology platform by scientists at GenSci.

Genfulin, Jintropin, Scimax are trademarks of GenSci.

About GenSci

GenSci ( is the leading Chinese biopharmaceutical company that develops, manufactures and markets biological therapeutics focused on endocrinology and related areas, aiming at providing affordable and innovative biopharmaceutical products to patients. The company is privately-held and headquartered in Changchun, China. Products include: Jintropinsomatropin (rhGH for injection), Jintropin AQ somatropin liquid pen, Scimax filgrastim (rhG-CSF injection), Granmac molgramostim (rhGM-CSF for injection), Jintrotide (octreotide acetate for injection) and Jintrirelin (triptorelin acetate injection). For more information, visit
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 3, 2006
Previous Article:H&E Equipment Services Announces 2006 Third Quarter Earnings and Conference Call Date.
Next Article:Democratic Loss on November 7 Could "Kill" Small Business Administration, says American Small Business League.

Related Articles
Ligand Receives FDA Marketing Clearance for Targretin Gel; Approval Adds Fourth Product to Ligand's Specialty Oncology Products Business.
European CPMP Recommends Approval for Ligand's Panretin Gel; First Product for Ligand Europe.
Topical anesthetic.
Connetics Acquires PediaMed Sales Organization; Enters Pediatric Market with 80 Sales Territories; Announces Year-End 2005 Velac Transaction; Updates...
Topical anesthetic.
Eisai Acquires Four Oncology-Related Products from Ligand.
GenSci's Profitability Remains Number One Among Chinese Biotech Companies.
Antares Receives First FDA Approval of ATD(TM) Gel Platform.
BioSante Pharmaceuticals Announces Issuance of New Patent Covering Elestrin(TM) and LibiGel(R).

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters